Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07, Zacks reports.
Indaptus Therapeutics Stock Up 0.6 %
INDP traded up $0.01 during trading on Wednesday, hitting $1.68. 2,931 shares of the stock were exchanged, compared to its average volume of 45,080. The firm has a market capitalization of $14.35 million, a P/E ratio of -0.94 and a beta of 1.39. Indaptus Therapeutics has a 1-year low of $1.56 and a 1-year high of $4.08. The stock has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $2.16.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a report on Monday, June 17th.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
See Also
- Five stocks we like better than Indaptus Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- Brinker International’s Price Dip is an Appetizing Entry Point
- Transportation Stocks Investing
- 3 Stocks That Could Beat the September Blues
- How to Use Stock Screeners to Find Stocks
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.